Stem Cell Therapy International Engages Auditors Pender Newkirk & Co.

TAMPA, Fla. -- Stem Cell Therapy International, Inc., (OTC: ATYD-News), a company in the field of regenerative medicine that specializes in the treatment of patients with stem cell transplantation therapy as well as being a global supplier of biological solutions containing new lines of stem cell products, has retained the services of Florida-based Pender Newkirk & Co., as its auditors (http://www.pnccpa.com).

Pender Newkirk & Co., one of Tampa Bay's largest locally owned accounting firms, has been serving businesses and individuals in the greater Tampa Bay area as well as throughout the United States and internationally since 1976. Its large client base of public companies is testimony to its expertise in auditing and assisting public companies in fulfilling Securities and Exchange Commission reporting requirements.

Calvin Cao, chief executive officer, said, "Pender, Newkirk's extensive experience in accounting procedures, SEC regulations and tax laws will strengthen SCTI's ability to grow and expand our corporate operations, especially with regard to capital structure, acquisitions, and developing plans for strategic partnerships."

Stem cell transplantation therapy is a field of medicine, which uses techniques and technologies that rely on replacing diseased, damaged or dysfunctional cells with healthy, functioning ones. This therapy is similar to the process of organ transplantation, only the treatment consists of the transplantation of stem cells into the body rather than entire organs, thus eliminating any chance of rejection or the need for immunosuppression drugs. These new techniques are being applied to finding a cure for a wide range of human disorders, including neurological diseases such as Alzheimer's, Parkinson's Disease, ALS (Lou Gehrig's disease), leukemia, muscular dystrophy, multiple sclerosis, arthritis, spinal cord injuries, brain injury, stroke, heart disease, liver and retinal disease, diabetes as well as certain types of cancer and the side effects of chemotherapy.

With the enactment of Proposition 71 in California in November 2004, a fund of $3 billion was created to fund stem cell research. Since then three other states New Jersey, Connecticut and Illinois, have allocated funds for stem cell research. Among the leading public companies in the U.S. in the field of stem cell technology are A.C.T. Holdings, Inc.; ViaCell; Geron; StemCells, Inc., and Aastrom Biosciences Inc. For additional information, please visit our website at www.scticorp.com.

About Stem Cell Therapy International (SCTI)

Stem Cell Therapy International, Inc. (SCTI) is in the field of regenerative medicine. SCTI provides new stem cell solutions, which are being used in the treatment of patients suffering from degenerative disorders of the human body. SCTI operates in conjunction with advanced medical facilities devoted to the treatment of human physical disorders with stem cell transplantation therapy. The company intends to establish relationships with highly specialized, professional medical treatment centers outside of the United States that will treat patients with the stem cell transplantation therapy. In addition, SCTI intends to provide biological solutions containing new stem cell products in the United States to universities, institutes and privately funded laboratory facilities for research purposes and clinical trials.

About Pender Newkirk & Company

Pender Newkirk & Company is one of Tampa Bay's largest locally owned accounting firms and has been serving Florida businesses and individuals since 1976. We are a quality-oriented firm with many successful, long-time clients. Our focus is to provide top-notch business services via a team of talented specialists with the responsiveness, personal service and fee schedule of a local organization. PNC is a sensible alternative to the international accounting firms as well as a logical next step for companies and individuals who have outgrown their current accounting firm's capabilities.

Forward Looking Statements

This report includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, product development acceptance, and the impact of competitive services and pricing and general economic risks and uncertainties.